Infectious Complications of Kidney Transplantation
By:
John P. Vella Division of Nephrology and Transplantation, Maine Medical Center, and Tufts University School of Medicine, Portland, Maine

Search for other papers by John P. Vella in
Current site
Google Scholar
PubMed Close
and
Alexander C. Wiseman Division of Renal Diseases and Hypertension, Transplant Center, University of Colorado Denver, Aurora, Colorado

Search for other papers by Alexander C. Wiseman in
Current site
Google Scholar
PubMed Close
Volume/Issue:
Volume 18: Issue 5
Published Online:
Nov 2019
Restricted access
Purchase Print On-Demand ASN Members Sign In Here
  • Collapse
  • Expand
Cover Nephrology Self-Assessment Program
Copyright:
© American Society of Nephrology 2019
Page Count:
0
Article Category:
Research Article
Print Publication Date:
01 Nov 2019
Published Online:
Nov 2019
  • 1.

    Heo NY, Mannalithara A, Kim D, Udompap P, Tan JC, Kim WR: Long-term patient and graft survival of kidney transplant recipients with hepatitis C virus infection in the United States. Transplantation 102: 454–460, 2018 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Dörr G, Del Bello A, Abravanel F, Marion O, Cointault O, Ribes D, et al.: Malignancies in hepatitis C virus-positive and -negative kidney transplant recipients: A case-controlled study. Transpl Infect Dis 19: 2017 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Gupta G, Kang L, Yu JW, Limkemann AJ, Garcia V, Bandyopadhyay D, et al.: Long-term outcomes and transmission rates in hepatitis C virus-positive donor to hepatitis C virus-negative kidney transplant recipients: Analysis of United States national data. Clin Transplant 31: 2017 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    McCauley M, Mussell A, Goldberg D, Sawinski D, Molina RN, Tomlin R, et al.: Race, risk, and willingness of end-stage renal disease patients without hepatitis C virus to accept an HCV-infected kidney transplant. Transplantation 102: e163–e170, 2018 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Chascsa DM, Mousa OY, Pungpapong S, Zhang N, Chervenak A, Nidamanuri S, et al.: Clinical outcomes of hepatitis C treatment before and after kidney transplantation and its impact on time to transplant: A multicenter study. Am J Transplant 18: 2559–2565, 2018 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Colombo M, Aghemo A, Liu H, Zhang J, Dvory-Sobol H, Hyland R, et al.: Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: A randomized trial. Ann Intern Med 166: 109–117, 2017 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Fernández I, Muñoz-Gómez R, Pascasio JM, Baliellas C, Polanco N, Esforzado N, et al.: Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C. J Hepatol 66: 718–723, 2017 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Huang H, Tang H, Deng H, Shen J, Zhou Q, Xie W, et al.: Treatment of chronic hepatitis C viral infection with sofosbuvir and daclatasvir in kidney transplant recipients. Transpl Infect Dis 21: e13018, 2019 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Lin MV, Sise ME, Pavlakis M, Amundsen BM, Chute D, Rutherford AE, et al.: Efficacy and safety of direct acting antivirals in kidney transplant recipients with chronic hepatitis C virus infection. PLoS One 11: e0158431, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Lubetzky M, Chun S, Joelson A, Coco M, Kamal L, Ajaimy M, et al.: Safety and efficacy of treatment of hepatitis C in kidney transplant recipients with directly acting antiviral agents. Transplantation 101: 1704–1710, 2017 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Sawinski D, Shelton BA, Mehta S, Reed RD, MacLennan PA, Gustafson S, et al.: Impact of protease inhibitor-based anti-retroviral therapy on outcomes for HIV+ kidney transplant recipients. Am J Transplant 17: 3114–3122, 2017 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Boyle SM, Malat G, Harhay MN, Lee DH, Pang L, Talluri S, et al.: Association of tenofovir disoproxil fumarate with primary allograft survival in HIV-positive kidney transplant recipients. Transpl Infect Dis 19: 2017 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Ebcioglu Z, Liu C, Shapiro R, Rana M, Salem F, Florman S, et al.: Belatacept conversion in an HIV-positive kidney transplant recipient with prolonged delayed graft function. Am J Transplant 16: 3278–3281, 2016 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Kuten SA, Patel SJ, Baru A, Gaber AO, Crutchley RD, Ramanathan V, et al.: Belatacept conversion in an HIV-positive kidney transplant recipient following anti-thymocyte globulin induction. Transpl Infect Dis 19: 2017 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Muller E, Barday Z: HIV-positive kidney donor selection for HIV-positive transplant recipients. J Am Soc Nephrol 29: 1090–1095, 2018 PubMed

  • 16.

    Ailioaie O, Arzouk N, Valantin MA, Tourret J, Calin RO, Turinici M, et al.: Infectious complications in HIV-infected kidney transplant recipients. Int J STD AIDS 29: 341–349, 2018 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Sawinski D, Lee DH, Doyle AM, Blumberg EA: Successful posttransplant treatment of hepatitis C with ledipasvir-sofosbuvir in HIV+ kidney transplant recipients. Transplantation 101: 974–979, 2017 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Locke JE, Shelton BA, Reed RD, MacLennan PA, Mehta S, Sawinski D, et al.: Identification of optimal donor-recipient combinations among human immunodeficiency virus (HIV)-positive kidney transplant recipients. Am J Transplant 16: 2377–2383, 2016 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Natori Y, Humar A, Husain S, Rotstein C, Renner E, Singer L, et al.: Recurrence of CMV infection and the effect of prolonged antivirals in organ transplant recipients. Transplantation 101: 1449–1454, 2017 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Gatault P, Al-Hajj S, Noble J, Chevallier E, Piollet M, Forconi C, et al.: CMV-infected kidney grafts drive the expansion of blood-borne CMV-specific T cells restricted by shared class I HLA molecules via presentation on donor cells. Am J Transplant 18: 1904–1913, 2018 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Higdon LE, Trofe-Clark J, Liu S, Margulies KB, Sahoo MK, Blumberg E, et al.: Cytomegalovirus-responsive CD8+ T cells expand after solid organ transplantation in the absence of CMV disease. Am J Transplant 17: 2045–2054, 2017 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Meesing A, Abraham RS, Razonable RR: Clinical correlation of cytomegalovirus infection with CMV-specific CD8+ T-cell immune competence score and lymphocyte subsets in solid organ transplant recipients. Transplantation 103: 832–838, 2019 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Jarque M, Melilli E, Crespo E, Manonelles A, Montero N, Torras J, et al.: CMV-specific cell-mediated immunity at 3-month prophylaxis withdrawal discriminates D+/R+ kidney transplants at risk of late-onset CMV infection regardless the type of induction therapy. Transplantation 102: e472–e480, 2018 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Vincenti F, Budde K, Merville P, Shihab F, Ram Peddi V, Shah M, et al.: A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor. Am J Transplant 18: 2945–2954, 2018 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Mallat SG, Tanios BY, Itani HS, Lotfi T, McMullan C, Gabardi S, et al.: CMV and BKPyV infections in renal transplant recipients receiving an mTOR inhibitor-based regimen versus a CNI-based regimen: A systematic review and meta-analysis of randomized, controlled trials. Clin J Am Soc Nephrol 12: 1321–1336, 2017 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Leboeuf C, Wilk S, Achermann R, Binet I, Golshayan D, Hadaya K, et al.; Swiss Transplant Cohort Study: BK polyomavirus-specific 9mer CD8 T cell responses correlate with clearance of BK viremia in kidney transplant recipients: First report from the Swiss Transplant Cohort Study. Am J Transplant 17: 2591–2600, 2017 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Gupta G, Kuppachi S, Kalil RS, Buck CB, Lynch CF, Engels EA: Treatment for presumed BK polyomavirus nephropathy and risk of urinary tract cancers among kidney transplant recipients in the United States. Am J Transplant 18: 245–252, 2018 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Thangaraju S, Gill J, Wright A, Dong J, Rose C, Gill J: Risk factors for BK polyoma virus treatment and association of treatment with kidney transplant failure: insights from a paired kidney analysis. Transplantation 100: 854–861, 2016 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Abend JR, Changala M, Sathe A, Casey F, Kistler A, Chandran S, et al.: Correlation of BK virus neutralizing serostatus with the incidence of BK viremia in kidney transplant recipients. Transplantation 101: 1495–1505, 2017 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Wunderink HF, Haasnoot GW, de Brouwer CS, van Zwet EW, Kroes ACM, de Fijter JW, et al.: Reduced risk of BK Polyomavirus infection in HLA-B51-positive kidney transplant recipients. Transplantation 103: 604–612, 2019 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Plafkin C, Singh T, Astor BC, Parajuli S, Bhutani G, Safdar N, et al.: Kidney transplant recipients with polycystic kidney disease have a lower risk of post-transplant BK infection than those with end-stage renal disease due to other causes. Transpl Infect Dis 20: e12974, 2018 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Waller KMJ, Wyburn KR, Shackel NA, O’Leary MJ, Kelly PJ, Webster AC: Hepatitis transmission risk in kidney transplantation (the HINT study): A cross-sectional survey of transplant clinicians in Australia and New Zealand. Transplantation 102: 146–153, 2018 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Masutani K, Omoto K, Okumi M, Okabe Y, Shimizu T, Tsuruya K, et al.; Japan Academic Consortium of Kidney Transplantation (JACK) Investigators.: Incidence of hepatitis B viral reactivation after kidney transplantation with low-dose rituximab administration. Transplantation 102: 140–145, 2018 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Mulley WR, Le ST, Ives KE: Primary seroresponses to double-dose compared with standard-dose hepatitis B vaccination in patients with chronic kidney disease: A systematic review and meta-analysis. Nephrol Dial Transplant 32: 136–143, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Querido S, Weigert A, Adragão T, Rodrigues L, Jorge C, Bruges M, et al.: Risk of hepatitis B reactivation in hepatitis B surface antigen seronegative and core antibody seropositive kidney transplant recipients. Transpl Infect Dis 21: e13009, 2019 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Jeon JW, Kim SM, Cho H, Baek CH, Kim H, Shin S, et al.: Presence of hepatitis B surface antibody in addition to hepatitis B Core antibody confers protection against hepatitis B virus infection in hepatitis B surface antigen-negative patients undergoing kidney transplantation. Transplantation 102: 1717–1723, 2018 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Pourbaix A, Ouali N, Soussan P, Roque Afonso AM, Péraldi MN, Rondeau E, et al.: Evidence of hepatitis E virus transmission by renal graft. Transpl Infect Dis 19: 2017 PubMed

  • 38.

    Mallet V, Sberro-Soussan R, Roque-Afonso AM, Vallet-Pichard A, Deau B, Portal A, et al.: Transmission of hepatitis E virus with plasma exchange in kidney transplant recipients: A retrospective cohort study. Transplantation 102: 1351–1357, 2018 PubMed

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 121 60 11
Full Text Views 109 33 4
PDF Downloads 181 50 5